BCTXZ
BriaCell Therapeutics Corp.
NASDAQ · Healthcare · Biotechnology · CA
$0.11
+3.99%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | (52.8K) | — | — | — | — |
| Cost of Revenue | 26.4K | — | 107.9K | — | — |
| Gross Profit | (26.4K) | — | (107.9K) | — | — |
| Operating Expenses | |||||
| R&D Expense | 29.2M | 29.2M | 21.5M | 27.2M | 15.3M |
| SG&A Expense | 6.8M | 6.8M | 5.9M | 6.2M | 7.9M |
| General & Admin Expense | 6.8M | 6.8M | — | 6.2M | 7.9M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 359.7K | — | — | — | — |
| Total Operating Expenses | 36.4M | 36.1M | 27.4M | 33.3M | 23.3M |
| Cost and Expenses | 28.8M | — | 27.5M | 33.3M | 23.3M |
| Operating Income (EBIT) | (32.4M) | — | (27.5M) | (33.3M) | (23.3M) |
| Non-Operating | |||||
| Interest Income | 250.6K | — | 121.4K | 288.0K | 891.2K |
| Interest Expense | — | — | 37.4K | — | — |
| Net Interest Income | 154.1K | — | 84.0K | 288.0K | 891.2K |
| Other Non-Op Income/Expense | (45.0M) | — | 656.6K | 28.4M | 3.0M |
| Non-Operating Income (excl Interest) | — | — | — | (28.4M) | — |
| EBT (Pre-Tax Income) | (84.6M) | (34.9M) | (26.9M) | (4.9M) | (20.3M) |
| Income Tax Expense | (3.5M) | — | — | — | — |
| Bottom Line | |||||
| Net Income | (34.9M) | (34.9M) | (26.6M) | (4.8M) | (20.3M) |
| Earnings from Cont. Ops | (34.9M) | (34.9M) | (26.9M) | (4.9M) | (20.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (34.9M) | (34.9M) | (26.6M) | (4.8M) | (20.3M) |
| Per Share | |||||
| Basic EPS | ($6.97) | ($6.97) | ($62.95) | ($43.68) | ($195.00) |
| Diluted EPS | ($6.97) | ($6.97) | ($62.95) | ($43.68) | ($195.00) |
| Revenue Per Share | ($0.01) | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 5.0M | 5.0M | 423114 | 109699 | 104131 |
| Diluted Shares Outstanding | 5.0M | 5.0M | 423114 | 109699 | 104131 |
| Profitability Metrics | |||||
| EBITDA | (77.6M) | — | (27.4M) | (4.8M) | (23.3M) |
| D&A | 155.7K | — | 107.9K | 83.9K | 15.3K |
| EBIT | (15.9M) | — | (27.5M) | (4.9M) | (23.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jul 1, 2026